Overall decision regret for 16.9% of patients; more regret for RP than radiotherapy component.
Survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both.
Men who used the medications prior to radical prostatectomy had 83% greater odds of Gleason 7-10 tumors compared with non-users.
Prostatectomy and radiotherapy with or without ADT reduced prostate cancer-specific and all-cause mortality rates.
Androgen deprivation increased all-cause mortality risk by 77% among black men who underwent brachytherapy for favorable-risk prostate cancer.
An analysis of individual participant data from 15 prospective studies suggests a protective effect.
Prostate cancer was diagnosed in 19.5% of PDE5i users vs 22.7% of nonusers, a statistically insignificant difference.
Skeletal-related events occurred in 38% of patients with metastatic castration-resistant prostate cancer.
ADT for prostate cancer may be associated with a reduced risk of inflammatory bowel disease.
Ethnicity, education identified as factors that influence patients treatment decisions.
Prevalence of obesity is high in adults with a history of breast, prostate, or colorectal cancer.
External beam radiation therapy (EBRT) plus brachytherapy found to offer improved systemic control versus EBRT alone and radical prostatectomy.
No significant differences observed in standard oncologic outcomes and quality of life at 12 weeks.
Blacks found to be slightly more likely than whites to leave observational management to undergo radiotherapy or surgery.
Study finds no greater burden from untreated cancer among active surveillance patients.
Three quarters of PCa deaths occur among men diagnosed with the disease when they are 70 to 89 years old.
Cabozantinib did not increase survival of heavily treated patients with mCRPC, compared with prednisone.
Research emphasizes the need for nationwide refinements in the prostate cancer screening process.
In a small study, some men whose cancer progressed while on enzalutamide had a profound PSA response to pembrolizumab.
Adjusted odds ratio of prostate cancer significantly higher for MRI score than PSA.
Largest Asian series to date shows a 5-year biochemical recurrence-free survival rate of 76.4%.
Swedish researchers say their findings are more useful for counseling men with a family history of prostate cancer.
Study results strengthen researchers' arguments for further clinical trials evaluating the potential protective effect of statins.
Combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated, researchers say.
Preliminary findings suggest a field effect in prostate cancer.
Urologists in Australia less favorable toward adjuvant radiotherapy in 2015 vs 2012.
Odds of using this strategy are 2.7-fold greater vs community facilities.
Genetic testing results could help guide therapy for advanced prostate cancer.
For localized prostate cancer patients, hypofractionated radiation therapy at a dose of 60 Gy in fractions is effective.
About 10% of patients with clinically localized prostate cancer have lymphovascular invasion on their prostatectomy specimen.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)